SCHEMBL4757589

SCHEMBL4757589

CC(=O)Nc1ncc([C]=O)cn1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.44
CYP1A2 P05177 4/20 0.39
KDM4E B2RXH2 2/20 0.38
CYP2C19 P33261 2/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
ALDH1A1 P00352 1/20 0.38
HPGD P15428 1/20 0.38
RAB9A P51151 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
PTK2 Q05397 1/20 0.38
POLB P06746 1/20 0.37
LMNA P02545 2/20 0.36
HTT P42858 1/20 0.36
ADORA3 P0DMS8 2/20 0.36
HSP90AA1 P07900 1/20 0.36
HSP90AB1 P08238 1/20 0.36
ADORA1 P30542 1/20 0.36
ACACB O00763 3/20 0.35
CYP2C9 P11712 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30496406 0.82 L3MBTL1 (0.53) L3MBTL1CYP1A2KDM4ECYP2C19MEN1
SCHEMBL4756227 0.81 LMNA (0.40) KDM4EKMT2AALDH1A1HPGDRAB9A
SCHEMBL13304496 0.77 ADORA3 (0.46) L3MBTL1CYP1A2KDM4ECYP2C19ALDH1A1
SCHEMBL14069596 0.77 LMNA (0.45) L3MBTL1CYP1A2KDM4ECYP2C19MEN1
SCHEMBL4756265 0.76 PTK2 (0.59) L3MBTL1CYP1A2KDM4ECYP2C19MEN1
SCHEMBL2275255 0.75 MEN1 (0.43) L3MBTL1CYP1A2KDM4ECYP2C19MEN1
SCHEMBL1069160 0.75 L3MBTL1 (0.42) L3MBTL1CYP1A2KDM4ECYP2C19MEN1
SCHEMBL10588098 0.75 L3MBTL1 (0.42) L3MBTL1CYP1A2KDM4ECYP2C19MEN1
SCHEMBL944470 0.75 LMNA (0.44) L3MBTL1CYP1A2KDM4ECYP2C19MEN1
SCHEMBL11470783 0.75 PTK2 (0.58) L3MBTL1CYP1A2KDM4EMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008133344-A2 PIPERIDINE DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-11-06 WO claimed
US-20080275085-A1 Piperidine derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-11-06 US claimed
WO-2008133344-A2 PIPERIDINE DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-11-06 WO disclosed
US-20080275085-A1 Piperidine derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-11-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080275085-A1 Piperidine derivative and use thereof TACR2, TACR1, PRLHR L3MBTL1 1776/4885CYP1A2 4132/4885KDM4E 583/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.